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Abstract: 
Background: risk and benefits of warfarin therapy in hemodialysis (HD) patients with fibrillation (AF) remains 
controversial. The aim of meta-analysis to evaluate risks of stroke and bleeding of warfarin treatment in these 
populations. 
 Methods and results: Relevant literatures were searched using the following electronic databases without any 
language restrictions: the Cochrane Library Database, PubMed, ISI, Ovid, and Chinese Biomedical Database from 
the building of the database to 2018. The studies were included if (a) studies described the risk of stroke or bleeding 
with or without warfarin in dialysis patients with AF, (b) studies provided information about hazard ratio (HR) and 
95% confidence interval (CI) of stroke or bleeding, and (c) the study design should be a clinical cohort. Sensitivity 
analyses and publication bias were also performed. We identified 6 eligible studies with a total of 9816 patients. 
Combined HRs showed that warfarin cannot provide a prevention for strokes in HD patients with AF [HR = 1.23, 
95% CI 0.80 - 1.87; P = 0.347], but associated with a higher risk of bleeding (HR = 1.20, 95% CI 1.03 - 1.39; P = 
0.019).  
Conclusion: This meta-analysis suggested that warfarin should not be recommended for the routine treatment of 
HD patients with AF. 
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INTRODUCTION: 
Atrial fibrillation (AF) is the most common 
arrhythmia in the general population and it’s 
associated with an increased chances of stroke that 
can be predicted using the CHADS2 score [1]. (Fig 1) 
Compared with the general population, patients who 
receive maintenance dialysis have a 6-fold higher risk 
of atrial fibrillation, and a 5- to 10-fold higher risk of 
ischemic stroke. [2-4] The prevalence of atrial 
fibrillation (AF) in hemodialysis (HD) population is 
high, ranging from 7 to 27%. [5] Warfarin is 
indicated in patients with AF for prophylaxis of 
stroke, preventing approximately 60% of strokes. [6] 
The greatest accepted risk with warfarin is bleeding, 
but there is also emerging evidence that warfarin may 
contribute to vascular calcification and precipitate 
calcific uremic arteriolopathy in patients with end-
stage renal disease (ESRD).[7] 
 Although warfarin is widely used in the dialysis 
patients for a numbers of indications, the exclusion of 
chronic dialysis recipients from randomized 
controlled trials of warfarin in patients with atrial 
fibrillation has led to uncertainty concerning its role 
in ischemic stroke prevention in this population. 
Many cohort studies [8] also stated that warfarin 
increased risk of stroke in HD patients with AF. HD 
patients with AF used warfarin if the CHA2DS2-
VASc score > 2 (fig 1) was recommended by 
AHA/ACC 2014 guidelines. In contrast Olesen et al. 
[9] found that warfarin was correlated with a 
significantly decreased risk of stroke.  
Because of the uncertainty in this area, recent 
guidelines have expressed appropriate caution 
regarding the use of warfarin anticoagulation in 
patients with atrial fibrillation who receive dialysis. 
To comprehensively synthesize information in this 
controversial area, this   meta-analysis is conducted 
to evaluate the safety and efficacy of warfarin in 
chronic dialysis patients with atrial fibrillation. 
 
Fig: 1 CHADS2 score and CHA2DS2-VASc score 
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METHOD: 
Search strategy: 
Selected articles were searched using the following 
electronic databases without Cochrane Library 
Database, PubMed, ISI, Ovid, and, Medline, Chinese 
Biomedical Database from the building of the 
database to 2018. By using mesh terms includes 
warfarin, hemodialysis/dialysis, and atrial fibrillation. 
The related research references were also reviewed. 
 
Inclusion criteria:  
The studies were included if (a) studies described the 
risk of stroke or bleeding with or without warfarin in 
dialysis patients with AF, (b) studies provided 
information about hazard ratio (HR) and 95% 
confidence interval (CI) of stroke or bleeding, and (c) 
the study design should be a clinical cohort.  
 
Data extraction:  
data was extracted from the  following selected  each 
article: first author’s last name, year of publication, 
number of patients, follow-up period, dialysis types, 
HR for stroke, HR for bleeding. Discrepancies were 
settled by a meeting consensus.  
 
Assessment of study quality:  
The study quality was checked by using the 
Newcastle– Ottawa Scale (NOS) for cohort studies in 
meta-analysis [10], the star evaluates three main 
categories: selection, comparability, and outcome. A 
study can be awarded a maximum of one star for each 
numbered item within the selection and outcome 
categories. A maximum of two stars can be given for 
comparability. A total score of seven or more stars 
was considered as a high-quality study.  
 
Statistical analysis: 
A combined hazard ratio (HR), with 95% confidence 
interval (CI) was calculated by STATA statistical 
software (Version 12.0). Heterogeneity among studies 
was estimated by Cochrane's Q-statistic and I2 tests. 
A random-effect model was used when Q-test 
exhibits a P < 0.05 or I2 test shows > 50%; otherwise, 
the fixed-effect model was selected. To explore the 
sources of heterogeneity, subgroup analysis was 
performed. Subgroup meta-analyses were based on 
dialysis types. Sensitivity analyses were conducted in 
the meta-analysis to inspect the influence of an 
individual study. Publication bias was assessed by 
constructing a funnel plot and using Egger’s and 
Begg’s tests. A significant two-way P value for 
comparison was defined as P < 0.05.   
RESULTS:  
Literature selection:  
Six clinical cohort studies met the inclusion criteria. 
The study selection process was outlined in Figure 2. 
The six cohort studies were published between 2009 
and 2014, and enrolling a total of 9816 participants. 
The mean age of patient is 66.8, 68.1, and 68.9 years, 
respectively. [9] Chan et al [12] defined stroke 
outcome as hospitalization, death from ischemic or 
hemorrhagic stroke, or transient ischemic attack 
(TIA). Wizemann et al. defined stroke outcome as 
hospitalization, death from stroke or cerebrovascular 
events. Winkelmayer et al. defined stroke outcome as 
ischemic or hemorrhagic stroke. Olesen et al.  
Defined stroke outcome as hospitalization, death 
from stroke or systemic thromboembolism (ischemic 
stroke, peripheral artery embolism, or TIA). 
Wakasugi et al. defined stroke outcome as new 
ischemic stroke. Shah et al. defined stroke as the first 
hospital admission or emergency department visiting 
for ischemic cerebrovascular disease, TIA, or retinal 
infarct at any point during the follow-up period.  
  
Chan et al. [11] did not describe the bleeding 
definition. Wizemann et al. [12] had no data about 
hazard ratio of bleeding. Winkelmayer et al defined 
bleeding outcome as gastrointestinal bleeding. Olesen 
et al.defined bleeding outcome as hospitalization or 
death from gastrointestinal, intracranial, urinary tract, 
or air-way bleeding. Wakasugi et al. defined bleeding 
outcome as fatal bleeding or bleeding that required 
hospitalization. Shah et al.defined bleeding outcome 
as the first hospital admission or emergency 
department visiting for intracerebral bleeding, 
gastrointestinal bleeding, intraocular bleeding, 
hematuria, or unspecified location of bleeding at any 
point during the follow-up period. The details of the 
articles were summarized in Table 1. According to 
NOS, all studies were of high quality.  
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Figure 2: Selection of the studies included in the meta-analysis. 
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Warfarin use with the stroke risk: 
2466 out of 9816 participants in six studies were 
received warfarin. There was statistically 
heterogeneity among the results of the included 
studies (I2= 79.2%, P = 0.000, Figure 3), thus the 
random-effects model was selected. Meta-analysis 
showed that warfarin and the risk of stroke provided 
no statistically significant (HR = 1.23, 95% CI 0.80 - 
1.87; P = 0.347). Subgroup meta-analyses were based 
on dialysis types. In HD patients, there was 
statistically heterogeneity among the results of the 
included studies (I2= 53.5%, P = 0.092, Figure 3). 
Meta-analysis presented that warfarin increased the 
risk of stroke (HR = 1.57, 95% CI 1.09 - 2.25; P = 
0.015, 4 trials). In HD and PD patients, there was 
statistically heterogeneity among the results of the 
included studies (I2= 88.0%, P = 0.004, Figure 4). 
Meta-analysis showed that warfarin and the risk of 
stroke provided no statistically significant (HR = 
0.72, 95% CI 0.28 - 1.83; P = 0.492, 2 trials) 
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Fig 3: 
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Warfarin use with the bleeding risk  
1957 out of 6571 participants in five studies were received warfarin. There were no statistical heterogeneity in the 
related six studies (I2 = 20.4%, P = 0.285, Figure 4), thus the fixed-effects model was selected. Meta-analysis 
presented that warfarin increased the risk of bleeding (HR =  
1.20, 95% CI 1.03 - 1.39; P = 0.019).   
Sensitivity analyses and Publication bias  
Sensitivity analyses were carried out in accordance with the stroke. There was significantly effect on the result of the 
HR and 95% CI when Olesen et al.study was excluded (Figure 5). It was showed that this study had high sensitivity 
and poor stability. The Egger’s test and Begg’s funnel plot were used to detect publication bias (Figure 6). The 
Egger’s linear regression test (P = 0.807) and Begg’s rank correlation test (Pr >|z| = 0.707) provided no evidence of 
substantial publication  
bias.  
  
  
Figure  4:  Warfarin  use  and  the  risk  of  bleeding  in  hemodialysis  atrial  patients  with  
fibrillation.  
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Figure 7:  Egger’s test and Begg’s funnel plot (publication bias).    
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DISCUSSION: 
Up to date, there is not any randomized controlled 
clinical trial has been done to evaluate the efficacy of 
warfarin in HD patients with AF. It is mainly due to 
the disease has a low incidence. The meta-analysis 
showed that warfarin treatment and the risk of stroke 
provided no statistically significant (HR = 1.23, 95% 
CI 0.80 - 1.87; P = 0.347, Figures 3). Warfarin is 
indicated in patients with AF for prophylaxis of 
stroke, preventing approximately 60% of strokes. 
However, HD patients have a higher risk of clotting. 
Arterio-venous graft and tunneled central venous 
catheter render an increased risk of local or systemic 
thromboembolism in HD patients. Although the 
balance of risks and benefits of warfarin perform 
favorable in mild to moderate CKD patients with AF, 
as lack of evidence from randomized controlled trials 
in these populations, current and previous 
observational studies on warfarin therapy failed to 
offer recommendations regarding warfarin 
management. Therefore, the Canadian Cardiovascular 
Society atrial fibrillation guidelines published in 2012 
no longer recommend warfarin for AF patients 
undergoing dialysis for the primary prevention of 
stroke.   
 
We performed subgroup analysis according to the 
dialysis type. The results showed that dialysis type 
has impact on the heterogeneity. Moreover, from the 
sensitivity analyses, we infer that Olesen et al.is one 
of the main sources of heterogeneity.  
Bleeding is one of the major risks of warfarin therapy 
in AF patients, and the INR should be closely 
monitored. Our results believed that warfarin was 
associated with a higher risk of bleeding (HR = 1.20, 
95% CI 1.03 - 1.39; P = 0.019). Platelet dysfunction, 
regular exposure to heparins during HD, frequent 
antibiotic use, dietary restrictions, impaired 
nutritional status, and drug-drug interactions render 
anticoagulation unpredictable. Hemorrhagic 
complications may be minimized with frequent INR 
monitoring Warfarin administration at the end of the 
dialysis session is related to prominent INR stability, 
which finally reduces the risk of bleeding according 
to precise dose adaptation and optimum therapeutic 
observance.   
In a recent study, Praehause et al. analysed the quality 
of oral phenprocoumon treatment control in ESRD 
patients, suggested that phenprocoumon is not 
inferior to warfarin. The phenprocoumon therapeutic 
effect in HD patients with AF required to further 
verification. HD patients with AF generally suffer 
complications such as heart failure, hypertension, 
previous stroke and diabetes mellitus. These are 
factors that affect OAT administration and the 
CHADS2 scoring, therefore the risk of stroke cannot 
be evaluated properly. Yang et al. suggested an 
individualized risk stratification that includes 
bleeding diathesis consideration, CHADS2 scoring 
system and the consideration of antiplatelet therapy if 
oral anticoagulation is not used. Thet et al. also 
recommended an individualized approach to optimize 
all potential risk factors of bleeding and stroke.  
CONCLUSION: 
In conclusion, results suggested that warfarin should 
not be recommended for the routine treatment in HD 
patients with AF. Large scale, multi-centered, 
randomized controlled clinical trials should be 
performed to investigate the efficacy of warfarin 
treatment in HD and AF patients.  
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